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a  b  s  t  r  a  c  t
There  is little  cost-effectiveness  evidence  for breast  cancer  screening  with  mammography  in women
under  the  age  of  50 years,  or  over  the  age  of 70 years,  and  available  estimates  vary  widely.  The  Canadian
Task  Force  on  Preventive  Health  Care  (CTFPHC)  took cost-effectiveness  into  account  in their  recent  recom-
mendations  on  breast  cancer  screening,  but  no  data  are  available  from  a Canadian  setting.  We  constructed
a  microsimulation  model  using  data  from  the  Screening  Mammography  Program  of  British  Columbia  (BC)
and the  BC  Cancer  Registry.  Eight  screening  strategies  with varying  age  ranges  and  frequencies  were  com-
pared to  a reference  strategy  of  no screening.  Local  screening,  diagnostic,  and  treatment  costs,  and  utility
weights  from  the  literature  were  applied  to  health  states.  Cost-effectiveness  was  expressed  as  incre-
mental  cost-effectiveness  ratios  (ICER)  and  cost-effectiveness  acceptability  curves,  using  the  results  of
probabilistic  sensitivity  analysis.  The  most  cost-effective  strategies  were  biennial  screening  from  ages  50
to  69,  with  an  ICER  of $28,921/QALY,  and  biennial  screening  from  40 to  69,  with  an  ICER of $86,029/QALY.
Screening  women  ages  40–49  was  more  cost-effective  than  screening  women  ages  70–74,  which  con-
ﬂicts  with  the recommendations  of the  CTFPHC.  There  was,  however,  considerable  uncertainty  around
these  cost-effectiveness  results.  Regardless  of willingness-to-pay,  no single  strategy  was signiﬁcantly
more  likely  to be cost  effective  than the  others.  There  is  value  in  reducing  the uncertainty  around  these
cost-effectiveness  estimates,  to  better  inform  future  screening  policy.
Publis©  2014  The  Authors.  
ntroduction
Recommendations for breast cancer screening by the Canadian
ask Force on Preventive Health Care (CTFPHC) and the US Pre-
entive Services Task Force (USPSTF) have attracted controversy,
articularly their recommendations against routine mammogra-
hy in average-risk women 40–49 years old and women  over 75
ears, and their weak recommendation for screening for women
0–74 years old [1,2]. In women 40–49 years old, both task forces
oncluded that the potential harms of routine mammography out-
eighed the potential beneﬁts due to the lower breast cancer
isk and the higher risk of false positive screens. Meta-analysis of
creening trials in women aged 40–49 has indicated that screening
educes breast cancer mortality by 15% (RR 0.85; 95% CI: 0.75–0.96)
3], but the absolute impact on breast cancer mortality is small.
ore recently, the 25-year follow-up of the Canadian National
reast Screening Study reported no difference in breast cancer
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mortality with screening in women 40–49 years old (HR 1.09; 95%
CI: 0.80–1.49) [4] although the conﬁdence interval included the
15% reduction found in the meta-analysis [3]. The number needed
to invite to screening to prevent one breast cancer death within
11 years decreases rapidly with age, from 2108 in women 40–49
years old, to 721 in women  50–69 years, and 451 in women  70–74
years [2]. For women  over 75 years, the task forces also concluded
that the harms of screening outweighed the potential beneﬁt, due
to the high risk of overdiagnosis of breast cancer in these women
[1,2]. The models used in the USPSTF assessment reported that
screening women  from ages 70 to 79 resulted in an additional two
deaths avoided and 24 life-years gained per 1000 women, but with
an accelerating risk of overdiagnosis with age due to increasing
competing mortality [5].
The CTFPHC considered cost-effectiveness evidence in its rec-
ommendation; however, there is little data available on the
cost-effectiveness of screening in women under 50 or over 70 years
old, and no data from a Canadian setting. In women under 50,
the reported cost-effectiveness of biennial screening varies from
around $20,000 per life-year gained (LYG) [6] to $83,500/QALY
[7], with an incremental cost-effectiveness for annual screening
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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wig. 1. Model structure. Transition probability varies by age, screening interval, and
ancer stage at diagnosis where indicated. Background non-breast cancer mortality
s not shown.
ompared to biennial screening of $168,400/QALY [7]. Cost-
ffectiveness estimates of screening women 70–79 years old range
rom $5400–$18,223/QALY for screening every 3–4 years [8], and
rom $8119–$27,751/QALY [9] to as high as $73,855/LYG [10] and
82,063/LYG [11] for biennial screening. Targeting screening to
atients with multiple risk factors, such as dense breasts, family
istory, or previous biopsy [8], or targeting screening to patients
ith the highest predicted life expectancy [11] may  improve cost-
ffectiveness, but such stratiﬁcation is not widely used in practice.
The objective of our study was to calculate the cost-effectiveness
f population-based mammography screening strategies for the
rovince of British Columbia (BC), with particular emphasis on
omen 40–49 and 70–74 years old.
ethods
We  constructed a micro-simulation model (Fig. 1) to simulate
he outcomes of mammography screening over a lifetime time hori-
on for a cohort of 40-year-old women. Women  are assumed to be
reast cancer free at age 40; Monte Carlo methods are then used
o create simulated histories under eight screening strategies, with
arying starting ages (40 or 50 years), ending ages (69 or 74 years),
nd frequency (annual or biennial), and a reference group without
creening. Events included are false-positive mammograms, diag-
osis of breast cancer, death from breast cancer, and death from
ther causes. Only ﬁrst breast cancer diagnoses are included in the
odel. Overdiagnosis of breast cancer is not included as an explicittate in the model, but the risk of breast cancer in women sub-
ect to screening is allowed to be greater than when screening does
ot occur. Cancer states have survival curves associated with them,
hich determine the likelihood of death from breast cancer.r Policy 2 (2014) 97–102
In constructing the model we  used as much local data as pos-
sible. Cancer detection rates at screening, false positive rates, and
interval cancer rates, by age, time since last screen, and sequence
(ﬁrst vs. subsequent screen), were calculated using data from the
Screening Mammography Program of BC (SMPBC) and the BC Can-
cer Registry (BCCR) for 2000–2009 [12,13]. Survival by age at
diagnosis and mode of detection was also calculated from BCCR
data using deaths in the years 2002–2009. Life tables were used to
predict underlying all-cause mortality [14].
An important consideration in model construction was appro-
priately deﬁning breast cancer incidence and survival in the
absence of screening, to avoid healthy-user bias. We estimated
underlying cancer rates in screening participants using the
Weedon-Fekjær model [15], calibrated to observed overdiagnosis
rates [13,16,17].
The model was  validated by comparing simulated mammog-
raphy use and breast cancer mortality for a series of screening
strategies to the outcomes from six of the US Cancer Interven-
tion and Surveillance Monitoring Network (CISNET) models [5]. Our
results were well within the range of ﬁndings from the CISNET mod-
els. We also compared the mortality rate reduction observed in the
UK Age trial [18] to a simulated cohort of women aged 40–49 using
our model, and found that the simulated mortality reduction was
within one percentage point of the mortality reduction reported in
the trial.
To calculate the cost of screening and diagnostic procedures,
professional fees for diagnostic tests and biopsies were obtained
from the BC Medical Services Commission fee schedule [19], and
combined with procedure-speciﬁc case costs [20]. Test frequency
and distribution following an abnormal screen were obtained from
SMPBC data [21], and used to calculate an average weighted cost
(Table 1).
Breast cancer treatment costs (Table 1) were calculated by age
and stage at diagnosis using treatment records for women diag-
nosed and treated at the BC Cancer Agency (BCCA) in 2004–2007.
These costs include systemic therapy, radiotherapy and surgery
costs. Drug costs were used directly from pharmacy dispensing
records. A unit cost per fraction from the BCCA Radiotherapy
department was  applied to radiotherapy records, and unit costs of
surgical procedures were estimated by combining professional fees
with case cost estimates [19,20]. Costs in a patient’s last year of life,
if they died of breast cancer, were counted toward the end-of-life
phase, and costs in the ﬁrst year following diagnosis were assigned
to the initial treatment phase [22]. A cost estimate for additional
hospitalization was  added to the end-of-life phase [23]. All costs
are presented in 2010 Canadian dollars [24].
To adjust for quality of life, utilities for diagnostic mammog-
raphy, biopsy, breast cancer treatment by stage at diagnosis, and
metastatic disease were obtained from the literature [25–27]. For
two health states the best available utilities were obtained using
visual analog scales [25]; these were scaled up to be comparable to
standard gamble estimates [28].
Model-predicted breast cancer incidence, mode of detection,
breast cancer mortality, life-years, quality-adjusted life years
(QALY), and costs were reported for each screening strategy. We
also counted number of mammograms, number of false positives,
and number of biopsies. Costs and QALYs were discounted at 3.5%
per year [29]. Sensitivity analysis was  performed by varying can-
cer costs and utilities, screening and diagnostic costs and utilities,
false positive rate, mortality reduction, overdiagnosis rate, and dis-
count rate. Results are presented as incremental cost-effectiveness
ratios (ICERs), where incremental cost (C) is divided by incremental
effectiveness (E), and expressed as $/QALY [30]:
ICER = C
E
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Table  1
Costs and utility weights for model.
Cost Utility weight
Mean (SD) Mean (SD)
Unit costs for screening and diagnostics
Screening mammogram $70.60 (3.41) 1.00a
Diagnostic mammogram $119.42 (11.94) 0.842 (0.026)b
Biopsy $665.10 (19.62)
40–49 yrs 50–69 yrs ≥70 yrs Utility weight
Mean  (SD) Mean (SD) Mean (SD) Mean (SD)
Mean costs for ﬁrst year after breast cancer diagnosis, by stage and age group
In  situ $7800 (3682) $7956 (3657) $7399 (3524) 0.900 (0.010)
Stage  1 $15,167 (8469) $12,576 (6504) $9404 (4105) 0.790 (0.040)
Stage  2 $24,522 (14,005) $20,283 (11,461) $11,852 (7878) 0.720 (0.035)
Stage  3 $32,469 (17,841) $29,011 (16,212) $17,206 (12,436) 0.640 (0.040)
Stage  4 $21,858 (20,962) $17,208 (18,625) $7705 (7615) 0.389 (0.042)
40–49  yrs 50–69 yrs ≥70 yrs Utility weight
Mean  (SD) Mean (SD) Mean (SD) Mean (SD)
Mean costs for last year of life for breast cancer deaths, by age group
End-of-life $25,095 (11,469) $18,776 (6329) $22,733 (9656) 0.389 (0.042)
sk of biopsy; utility weight applied for two weeks.
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Fig. 2. Cost-effectiveness acceptability curves showing results of probabilistic sen-
sitivity analysis. Curves indicate the probability that the indicated screening strategy
is  the most cost-effective option for a given WTP  value. The dashed line is the cost-
effectiveness acceptability frontier, indicating the probability of cost-effectiveness
for  strategies with the highest expected net monetary beneﬁt. WTP  values for changea Not varied in probabilistic sensitivity analysis.
b Utility weight for diagnostic work-up, including diagnostic mammogram and ri
robabilistic sensitivity analysis was conducted using Monte Carlo
imulation with 1000 iterations, sampling from all model param-
ters. Results from probabilistic sensitivity analysis are used to
alculate 95% conﬁdence intervals (CI) around the mean cost and
ffectiveness estimates, to describe the variability arising from the
ncertainty in model parameters. Results are also interpreted using
he net beneﬁt framework, where net monetary beneﬁt (NMB):
MB  = ()E − C
nd  represents the cost-effectiveness threshold, or willingness-
o-pay (WTP), in $/QALY [30]. Results are presented for a range
f WTP  values as cost-effectiveness acceptability curves (CEAC),
llustrating uncertainty as the probability that a given screening
trategy is cost-effective at a given WTP, and as the expected value
f perfect information (EVPI), which describes in monetary terms
he value of acquiring additional information to eliminate uncer-
ainty [30,31].
esults
Mortality reduction increased with both frequency and age
ange, from 9.7% with biennial screening from 50 to 69 years, to
7.0% for annual screening from 40 to 74 years (Table 2). Overdiag-
osis was consistently higher for all screening strategies ending
t age 74 than for screening to age 69. False positive screens and
iopsies were consistently higher for screening strategies starting
t age 40 than those at age 50. Screening resulted in additional costs,
hich increased with the number of screens performed, from $430
95% CI: $30–$812), for biennial screening from 50 to 69 years to
1548 (95% CI: $1132–$1947), for annual screening from 40 to 74
ears (Table 2). All screening strategies resulted in a small increase
n mean effectiveness, although all 95% CIs crossed zero.
The ICER for biennial screening from 50 to 69 years relative to no
creening was $28,921/QALY (Table 2). As the screening age range
xpanded and frequency increased the ICERs increased to a maxi-
um  of $361,897/QALY for annual screening from 40 to 74 years,
elative to annual screening from 40 to 69 years. Biennial screening
rom 50 to 74 years, annual screening from 50 to 69 years, and
nnual screening from 50 to 74 years were dominated by the other
trategies (they are less effective or less cost-effective than the
lternative strategies) and do not form part of the cost-effectiveness
rontier (supplementary Fig. S1).points on the frontier are labeled. Abbreviations: QALY, quality-adjusted life-year;
WTP, willingness to pay.
Results of sensitivity analysis are illustrated using biennial
screening from 50 to 69 years (Table 3). The model was most sen-
sitive to changes in calibrated mortality reduction. In the base
case, the model was  calibrated to the 24% reduction in mortality
in women  40–49 years, corrected for non-compliance, in the UK
Age Trial. As the calibrated mortality reduction was varied from
20% to 40%, the ICERs decreased by an order of magnitude. Varying
diagnostic costs, treatment costs, diagnostic utilities, and treatment
utilities had a very small impact on cost-effectiveness.
There is signiﬁcant uncertainty around the cost-effectiveness
results. The CEAC (Fig. 2) indicates, for each screening strategy at
each possible cost-effectiveness threshold, the probability that the
strategy is the most cost-effective option (the proportion of simu-
lations where the given strategy had the highest net beneﬁt). The
probability that any given screening strategy is most cost-effective
does not exceed 25%, and the probability that ‘no screening’ has
100 R. Pataky et al. / Journal of Cancer Policy 2 (2014) 97–102
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Table 3
Deterministic sensitivity analysis for biennial screening, ages 50–69 years.
Biennial 50–69
Variable range ICER range
Mortality reduction 20%, 40%a $160,273, $16,135
Overdiagnosis rate 0%, 17%a $22,322, $33,392
False positive rate Mean − 1SD, mean + 1SD $27,885, $32,915
Screen cost $50, $120 $22,733, $46,958
Diagnostic costs $590, $950 $28,681, $30,938
Treatment costsc Mean − 1SD, mean + 1SD $30,097, $29,599
Diagnostic utility 0.684b, 1.00 $34,679, $26,198
Treatment utilityc Mean − 1SD, mean + 1SD $32,276, $27,760
Discount rate 0%, 6% $14,004, $51,030
Abbreviations: ICER, incremental cost-effectiveness ratio.
a Mortality reduction and overdiagnosis were varied by calibrating the model to
these values for women  aged 40–49 years.
b Utility weight applied for two weeks.
c Values for all cancer health states (in situ and Stages 1–4) were varied simulta-
neously.
the greatest beneﬁt does not reach zero, leveling out around 2.4%
at WTP  values above $320,000/QALY.
The cost-effectiveness acceptability frontier (Fig. 2) indicates the
optimal strategy for a given cost-effectiveness threshold, deﬁned as
the strategy with the highest expected NMB. Sample NMB  results
at WTP  values of $50,000/QALY and $100,000/QALY are provided
(Table 2). For most WTP  values the frontier does not follow the
outer limit of the CEAC. The distributions of NMB  from probabilistic
sensitivity analysis are skewed, and the strategy with the high-
est expected NMB  is not necessarily the strategy with the greatest
probability of being cost-effective.
The EVPI increases with WTP, and is $441 per woman screened
at a WTP  of $50,000/QALY and $997 at a WTP  of $100,000/QALY
(supplementary Fig. S2).
Interpretation
Whether mammography screening is cost-effective will depend
on institutional or jurisdictional willingness-to-pay, but our results
indicate that biennial screening from ages 50 to 69 is cost-effective
at WTP  values above $29,000/QALY, and biennial screening from
ages 40 to 69 is cost-effective at WTP  values from $86,000/QALY to
$106,000/QALY.
Focusing on the key issues of screening frequency and age
range, we  found that biennial screening strategies were more cost-
effective than annual screening strategies, and extending screening
to women  ages 40–49 was  more cost-effective than screening
beyond age 69. Compared to biennial screening from 50 to 69
years, it is more cost-effective to expand the age range to 40–74
years than to move to annual screening. For both annual and bien-
nial screening, screening from 50 to 74 years was dominated by
screening from 40 to 69 years. A similar pattern was found by Rojnik
et al. [32] who  used decision modeling methods to compare the
cost-effectiveness of screening age ranges and frequencies. In that
study, incrementally extending the age range toward younger ages
ﬁrst was most cost-effective [32]. These results indicate that within
a constrained budget, higher priority should be given to screening
women ages 40–49 years than to screening women over 70 years or
increasing screening frequency. This is in conﬂict with the recom-
mendations of the USPSTF and CTFPHC, which weakly recommend
screening women ages 70–74 and recommend against screening
women under 50 years old.More broadly, however, the results of our simulations highlight
the uncertainty around the effectiveness and cost-effectiveness
of screening, and the small absolute improvements in quality-
adjusted life expectancy. The 95% CIs for the incremental QALY
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stimates for all screening strategies cross zero, with between 9%
nd 15% of simulations resulting in a loss of QALYs. This is com-
arable to a recent model of the NHS breast screening program,
here screening led to a reduction in QALYs in 12% of scenarios [33].
ncremental QALY gains from increasing age range and frequency
re very small, and the results of probabilistic sensitivity analysis
ndicate that even at WTP  values as high as $350,000/QALY no sin-
le screening strategy is the most cost-effective more than 25% of
he time. This result is due in part to the large number of strate-
ies under consideration, and the commonalities among screening
trategies. There are very small differences in cost and effectiveness
etween strategies, leading to signiﬁcant overlap when uncertainty
s taken into account.
Our EVPI analysis indicates that eliminating the uncertainty
round these cost-effectiveness estimates, to strengthen the evi-
ence informing screening decisions, could be of signiﬁcant value.
VPI represents the consequences of uncertainty by measuring the
ean cost, as net beneﬁt forgone, of choosing a strategy that is not
he most cost-effective. For example, at a WTP  of $50,000/QALY,
iennial screening from ages 50 to 69 years would be the a pri-
ri preferred strategy, because it has an ICER below the threshold
alue and provides the greatest expected NMB at that threshold,
313. However, the CEAC indicates that this strategy is the most
ost-effective (provides the greatest NMB) in only 19% of simula-
ions. If we were able to hypothetically choose the strategy offering
he greatest NMB  in each simulation, using “perfect information”
ith no uncertainty, we could achieve an NMB  $441 higher than
hat we would expect from choosing our a priori preferred strat-
gy, biennial screening from ages 50 to 69. At a population level,
n EVPI of $441 per woman screened represents a large potential
eneﬁt forgone. Reducing this uncertainty, by improving estimates
f mortality reduction, costs, utility, and other potential harms
nd beneﬁts, will improve the cost-effectiveness estimates used
o inform policy decisions.
The main limitation of our analysis is the risk of uncon-
rolled confounding in observational data. By using observational
opulation-based data from the BCCR, SMPBC, and BCCA we  can be
onﬁdent that these results reﬂect the BC experience, but there
ay  be patient risk factors, regional differences, or system fac-
ors that introduce bias. The model is driven by differences in
creening outcomes observed from the SMPBC, rather than by
n underlying natural history model. As a result we have no
ay of holding background disease constant across all screening
trategies and simulations, which likely also contributes to the
ncertainty in model results. Furthermore, screening and treat-
ent practices have changed since 2000, the beginning of our
bservation period. Digital mammography is being introduced
cross BC, but ﬁlm mammography was in place during most of
he study period. This will have the effect of underestimating both
he effectiveness and the cost of screening; however, the differ-
nce is unlikely to be large. Previous studies have reported ICERs
or digital mammography versus ﬁlm of $180,333/LYG [34] and
331,000/QALY [35], suggesting that digital mammography may
egatively impact the cost-effectiveness of screening programs.
astly, our model assumes full participation and perfect adherence
o screening schedules. In BC, where biennial screening is currently
ecommended, overall participation among women aged 50–69 is
round 60%, with 45% of women returning 18–30 months after their
revious screen, 10% returning within 18 months, and 45% retur-
ing after 30 months or not at all. Both costs and effectiveness are
ffected by reduced adherence, but previous research by Arveau
t al. [36] indicates that relative changes in cost and effectiveness
ill be comparable, resulting in small changes in cost-effectiveness
stimates.
In summary, biennial screening from 50 to 69 years was most
ost-effective, with an ICER of $28,921/QALY, followed by biennial
[
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screening from 40 to 69 years with an ICER of $86,029/QALY.
Screening women from ages 70 to 74 provided little additional
beneﬁt, regardless of screening frequency. A challenge, however, is
interpreting these results in the context of signiﬁcant uncertainty.
Most screening strategies had overlapping CIs for cost and effec-
tiveness estimates, and no single strategy was  much more likely to
be cost-effective than the others, regardless of willingness-to-pay.
To better inform screening decisions, it is worthwhile to pursue
further information to reduce the uncertainty of cost-effectiveness
values.
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